Back in November 2020, Cassava priced its public offering at $8 per share. Proceeds of $75 million were meant to support the Phase 3 study. Since then, SAVA stock has traded as high as $146, without a ...
Shares of Cassava Sciences (NASDAQ: SAVA) were 5.3% lower as of 11:05 a.m. ET on Monday after falling as much as 19% earlier in the morning. The decline came on the heels of the federal indictment on ...
WASHINGTON (Reuters) - The U.S. Justice Department has opened a criminal investigation into Cassava Sciences Inc involving whether the biotech company manipulated research results for its experimental ...
Cassava Sciences, Inc. (SAVA) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...
Hosted on MSN
Cassava Sciences stock on track for worst day in about 9 months — what’s driving today’s selloff?
・Cassava said that it intends to work “expeditiously” with the FDA and address the items flagged by the agency. ・The company added that it no longer expects to initiate the trial in question in the ...
On the morning of Jan. 20, 2022, Texas-based clinical-stage biotechnology company Cassava Sciences (NASDAQ:SAVA) was trending on financial message board StockTwits as traders were buzzing about this ...
Shares of Cassava Sciences (NASDAQ: SAVA) were skyrocketing 29.6% higher as of 10:53 a.m. ET on Monday. The big gain came after executive chairman Rick Barry released an open letter to shareholders, ...
The controversy about alleged data manipulation related to simufilam was stirred up again by a leaked report. Cassava's response noted that the report from CUNY didn't make any findings of data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results